OHR PHARMACEUTICAL ANNOUNCES POSITIVE FINAL ANALYSIS OF PHASE II CLINICAL DATA FOR OHR-102 IN RETINAL VEIN OCCLUSION

OHR-102 Meets Primary Endpoint of Visual Acuity

Data Support a Phase III Development Program in Retinal Vein Occlusion

NEW YORK, New York – July XX, 2015 – Ohr Pharmaceutical, Inc. (NasdaqCM: OHRP), an ophthalmology research and development company, today announced positive results from the company's Phase II clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). Analysis showed that OHR-102 was well tolerated and met its primary endpoint of significant improved visual acuity. These results were statistically and clinically significant and no serious adverse events were observed in patients exposed to OHR-102.

The data were presented by John Wroblewski, MD, and Allen Hu, MD, retina specialists at Cumberland Valley Retinal Consultants on Saturday, July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS) in Vienna, Austria.

"These very promising final results demonstrate a significant treatment effect of Squalamine in combination with current therapy," said John Wroblewski, MD, principal investigator of this Phase II study. "The 38 week data confirms positive trends observed earlier, including meaningful effect on visual acuity and edema. All subjects treated with Squalamine achieved visual acuity and OCT stabilization during the trial with an average of 27.8 letters gained by week 38. This study suggests that OHR-12 combination therapy may provide benefit in the treatment of patients with macular edema or central retinal vein occlusion."

The 38 week Phase II clinical trial enrolled 20 treatment naïve patients with macular edema due to retinal vein occlusion. All patients received OHR-102 for the first ten weeks of treatment, with two injections of Lucentis given at week 2 and week 6. At week 38, the average mean letter gain was +7.4 for patients treated with OHR-102 compared with +3.1 in the control group. In measurement of the gain of any letters, the OHR-102 treated group reported a gain of 5-16 letters, an 80% increase, compared with a 50% gain (4-13 letters) in the control group. Additionally, the OHR-12 treated group reported no loss of letters (0%), compared with a loss of 1-9 letters (50%) in the control group.

"The positive results of this Phase II study exceeded our expectations and represent an important milestone for the development of OHR-102 in the treatment of retinal vein occlusion," said Dr.

Irach Taraporewala, CEO of Ohr. "The consistency of the efficacy data, combined with the favorable safety profile, warrants a Phase III program to confirm and extend these results."

Dr. Taraporewala continued, "I would like to thank the clinical investigators, coordinators, and patients for their participation in the study, whose efforts continue to allow us to advance this novel topical therapy for the treatment of retinal neovascular diseases."

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. is an ophthalmology research and development company whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several company-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases include wet-AMD, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:

Ohr Pharmaceutical Inc.	LifeSci Advisors, LLC
Investor Relations	Michael Wood
888-388-2327	646-597-6983
ir@ohrpharmaceutical.com	mwood@lifesciadvisors.com